LLY - CIK 0000059478
ELI LILLY & Co trades as LLY and has a market capitalization of $1.072 T, making it the #10 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $65.18B, up 44.7% from the prior year and net income of $20.64B. This page tracks ELI LILLY & Co through 989 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years ELI LILLY & Co's revenue grew from $18.31B to $65.18B, a compound annual growth rate of 15.1%. Net profit margin expanded from 14.9% to 31.7% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-20 |
| Insider sale notice | 144 | 2026-05-20 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| SD | - | 2026-05-11 |
| Prospectus supplement | 424B2 | 2026-05-08 |
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia | Eli Lilly and Company
Foundayo (orforglipron), a once-daily pill taken without food or water restrictions, was associated with reduced body weight of up to 13% in adults 65 and older with obesity or overweight, in new analysis of ATTAIN-1/2 | Eli Lilly and Company
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting | Eli Lilly and Company
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial | Eli Lilly and Company
The largest companies sharing ELI LILLY & Co's SEC industry classification (pharmaceutical preparations).
ELI LILLY & Co (LLY) has a market capitalization of $1.072 T as of 2026-06-10, ranking #10 among US-listed companies.
ELI LILLY & Co reported revenue of $65.18B for fiscal year 2025, an increase of 44.7% year over year.
Yes. ELI LILLY & Co reported net income of $20.64B in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference | Eli Lilly and Company